title: The effect of EGb 761 on the doxorubicin cardiomyopathy.
abstract: Doxorubicin (Dx) is used to treat a number of types of cancer. The drug produces many toxic reactions and cardiomyopathy. Many drugs have been used to prevent this myocardial damage caused by peroxidative alterations. EGb 761 is being used to prevent arrhythmias in ischemic myocardium. We decided to establish the tissue protective effect of EGb 761 against myocardial toxic effects of Dx in three groups of rats. Cardiotoxicity signs of Dx were found to be dose-related, beginning at 30 mg/kg dose and being apparent at 45 mg/kg dose. 48 hr after a single i.v. injection, myocardial tissues showed a marked edema, vacuolization and fragmentation. We compared the changes in heart tissue biochemically and histopathologically among the control, Dx treated and EGb 761 (100 mg/kg/d.x 4, i.p.) + Dx treated groups. Biochemical results of CK-MB and MDA values showed a significant decrease in Dx + EGb 761 group when compared with Dx treated group. Histopathologically, myocardial tissues of Dx + EGb 761 treated group were found to have diminished vacuolization and fragmentation. These results suggest that EGb 761 might have the same therapeutic potential in Dx related cardiomyopathy.
authors.affiliation: Gazi University, Faculty of Medicine, Department of Pharmacology, Ankara, Turkey.
authors.forename: O
authors.initials: O
authors.lastname: Timioğlu
authors.forename: S
authors.initials: S
authors.lastname: Kutsal
authors.forename: M
authors.initials: M
authors.lastname: Ozkur
authors.forename: O
authors.initials: O
authors.lastname: Uluoğlu
authors.forename: A
authors.initials: A
authors.lastname: Aricioğlu
authors.forename: C
authors.initials: C
authors.lastname: Cevik
authors.forename: E
authors.initials: E
authors.lastname: Düzgün
authors.forename: B
authors.initials: B
authors.lastname: Sancak
authors.forename: A
authors.initials: A
authors.lastname: Poyraz
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D000975:Antioxidants / Q000494:pharmacology*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects*; D005419:Flavonoids / Q000494:pharmacology*; D020441:Ginkgo biloba; D015227:Lipid Peroxidation / Q000187:drug effects; D008315:Malondialdehyde / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D010936:Plant Extracts; D051381:Rats; D000096983:Ginkgo Extract
chemical_list: D000903:Antibiotics, Antineoplastic; D000975:Antioxidants; D004317:Doxorubicin; D005419:Flavonoids; D008315:Malondialdehyde; D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract